Simone M C Spoorenberg1, Stefan M T Vestjens1, Ger T Rijkers2,3, Bob Meek2, Coline H M van Moorsel4,5, Jan C Grutters4,5, Willem Jan W Bos1. 1. Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands. 2. Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands. 3. Department of Sciences, University College Roosevelt, Middelburg, The Netherlands. 4. Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands. 5. Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVE: The aim of this study was to investigate the prognostic value of four biomarkers, YKL-40, chemokine (C-C motif) ligand 18 (CCL18), surfactant protein-D (SP-D) and CA 15-3, in patients admitted with community-acquired pneumonia (CAP). These markers have been studied extensively in chronic pulmonary disease, but in acute pulmonary disease their prognostic value is unknown. METHODS: A total of 289 adult patients who were hospitalized with CAP and participated in a randomized controlled trial were enrolled. Biomarker levels were measured on the day of admission. Intensive care unit admission, 30-day, 1-year and long-term mortality (median follow-up of 5.4 years, interquartile range (IQR): 4.7-6.1) were recorded as outcomes. RESULTS:Median YKL-40and CCL18 levels were significantly higher and levels of SP-D were significantly lower in CAP patients compared to healthy controls. Significantly higher YKL-40, CCL18 and SP-D levels were found in patients classified in pneumonia severity index classes 4-5 and with a CURB-65 score ≥2 compared to patients with less severe pneumonia. Furthermore, these three markers were significant predictors for long-term mortality in multivariate analysis and compared with C-reactive protein and procalcitonin level on admission, area under the curves were higher for 30-day, 1-year and long-term mortality. CA 15-3 levels were less predictive. CONCLUSION:YKL-40, CCL18 and SP-D levels were higher in patients with more severe pneumonia, possibly reflecting the extent of pulmonary inflammation. Of these, YKL-40 most significantly predicts mortality for CAP.
RCT Entities:
BACKGROUND AND OBJECTIVE: The aim of this study was to investigate the prognostic value of four biomarkers, YKL-40, chemokine (C-C motif) ligand 18 (CCL18), surfactant protein-D (SP-D) and CA 15-3, in patients admitted with community-acquired pneumonia (CAP). These markers have been studied extensively in chronic pulmonary disease, but in acute pulmonary disease their prognostic value is unknown. METHODS: A total of 289 adult patients who were hospitalized with CAP and participated in a randomized controlled trial were enrolled. Biomarker levels were measured on the day of admission. Intensive care unit admission, 30-day, 1-year and long-term mortality (median follow-up of 5.4 years, interquartile range (IQR): 4.7-6.1) were recorded as outcomes. RESULTS: Median YKL-40 and CCL18 levels were significantly higher and levels of SP-D were significantly lower in CAP patients compared to healthy controls. Significantly higher YKL-40, CCL18 and SP-D levels were found in patients classified in pneumonia severity index classes 4-5 and with a CURB-65 score ≥2 compared to patients with less severe pneumonia. Furthermore, these three markers were significant predictors for long-term mortality in multivariate analysis and compared with C-reactive protein and procalcitonin level on admission, area under the curves were higher for 30-day, 1-year and long-term mortality. CA 15-3 levels were less predictive. CONCLUSION:YKL-40, CCL18 and SP-D levels were higher in patients with more severe pneumonia, possibly reflecting the extent of pulmonary inflammation. Of these, YKL-40 most significantly predicts mortality for CAP.
Authors: Arindam Chakrabarti; Allen Nguyen; Margaret M Newhams; Maikke B Ohlson; Xiaoying Yang; Sheila Ulufatu; Shannon Liu; Summer Park; Min Xu; Jenny Jiang; Wendy G Halpern; Veronica G Anania; Jacqueline M McBride; Carrie M Rosenberger; Adrienne G Randolph Journal: Pediatr Pulmonol Date: 2021-12-07
Authors: Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel Journal: Hum Vaccin Immunother Date: 2021-11-10 Impact factor: 3.452
Authors: Simone M C Spoorenberg; Stefan M T Vestjens; G P Voorn; Coline H M van Moorsel; Bob Meek; Pieter Zanen; Ger T Rijkers; Willem Jan W Bos; Jan C Grutters Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Sebastian Majewski; Damian Tworek; Karolina Szewczyk; Justyna Kiszałkiewicz; Zofia Kurmanowska; Ewa Brzeziańska-Lasota; Hanna Jerczyńska; Adam Antczak; Wojciech Jerzy Piotrowski; Paweł Górski Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-07-22